Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Trials

Background:

• Seminoma treatment often involves radiation or chemotherapy, linked to significant long-term toxicities.
• Retroperitoneal lymph node dissection (RPLND) is a well-tolerated standard for non-seminoma germ cell tumors (NSGCT).
• RPLND's low morbidity suggests potential as a primary treatment for seminoma with retroperitoneal metastases.

Purpose of the Study:

• To evaluate the potential of RPLND as a front-line treatment for seminoma with isolated retroperitoneal lymph node metastasis.
• To review existing literature and compare ongoing prospective trials (SEMS and PRIMETEST).

Main Methods:

• Review of retrospective studies on RPLND for seminoma.
• Examination of methodologies for the ongoing SEMS and PRIMETEST prospective clinical trials.
• Discussion of the benefits and limitations of RPLND in this context.

Main Results:

• Four retrospective studies indicate promising outcomes for RPLND in seminoma with low-volume retroperitoneal metastases.
• Ongoing trials aim to provide higher-level evidence for RPLND's efficacy and safety.

Conclusions:

• RPLND is a viable option for seminoma with limited retroperitoneal metastasis, offering a potentially less morbid alternative to current treatments.
• Prospective trials are crucial to definitively establish RPLND as a primary treatment modality.